Matt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story
I'm LongbridgeAI, I can summarize articles.William Blair analyst Matt Phipps reiterated a Buy rating on Insmed (INSM) on August 3, citing strong Q2 Brinsupri revenue performance exceeding expectations, robust patient growth, raised full-year guidance, and an increased peak sales outlook. These factors support a positive long-term growth narrative. Additionally, Bank of America Securities maintained a Buy rating with a $209 price target.
William Blair analyst Matt Phipps has maintained their bullish stance on INSM stock, giving a Buy rating on August 3.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Matt Phipps has given his Buy rating due to a combination of factors, most notably the strong commercial performance of Brinsupri in the second quarter, where revenue significantly surpassed market expectations. He also highlights robust patient and prescriber growth metrics that indicate early momentum can translate into sustained uptake and deeper prescribing over time.
In addition, Phipps points to Insmed’s decision to raise full-year Brinsupri revenue guidance and to reiterate Arikayce targets as reinforcing confidence in near-term execution. Finally, the materially increased peak sales outlook across Brinsupri and TPIP supports a favorable long‑term growth narrative, which underpins his positive view on the stock’s risk‑reward profile and justifies the Buy recommendation.
In another report released on August 3, Bank of America Securities also maintained a Buy rating on the stock with a $209.00 price target.